LivingGLP1
Study S002775

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects

Registration

Registration
NCT06118021
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
DOUBLE
Status
COMPLETED
Enrollment
200
Start
2023-10-16
Primary completion
2024-08-13
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions
Overweight and Obesity
Interventions
DRUG:HS-20094; DRUG:Placebo
Results posted
FALSE

Registered primary outcomes

  • Percent Change from Baseline in Body Weight [From Week 0 to Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.